RESULTS
OSM and OSMR are highly expressed in IBD To identify additional cytokines that might promote IBD pathogenesis, we analyzed cytokine mRNA expression in intestinal mucosal biopsies from previously published cohorts of patients with clinically active CD (n = 162 with CD as compared to n = 42 controls without IBD; RNA-seq data) or UC (n = 74 with UC; n = 11 controls without IBD; Affymetrix microarray data) 16, 17 . 64 candidate cytokines with data available in both studies were examined. Of these, only four were significantly enriched in inflamed tissue in both cohorts, when compared to non-IBD controls: IL6, IL1A, IL1B, and OSM ( Fig. 1a and Supplementary Table 1 ). Of these cytokines, OSM is the least well characterized in the gut, and we therefore chose to investigate it further. Among untreated pediatric patients with newly diagnosed CD 16 , we found OSM to be the most highly and consistently expressed cytokine relative to those in healthy control mucosa ( Fig. 1b and Supplementary Table 1 ). Furthermore, OSM was particularly enriched in patients with deep mucosal ulcerations ( Fig. 1c) .
Although OSMR was similarly enriched in IBD mucosa, this was not true of LIFR or IL6ST (also known as gp130) ( Fig. 1c) .
To validate our initial findings, we used quantitative real-time PCR (RT-qPCR) to examine OSM and OSMR expression in freshly isolated biopsies from patients with IBD and from healthy controls who underwent routine endoscopy at the John Radcliffe Hospital, Oxford, UK (for associated clinical information, see Supplementary  Table 2 ). This analysis confirmed high expression of OSM and OSMR in tissue from patients with active IBD (Fig. 1d) . Furthermore, the expression of OSM and OSMR was closely correlated with histopathological disease severity (Fig. 1e) . No difference in the expression of either OSM or OSMR was observed between patients with CD or UC (Fig. 1f ). An analysis of transcriptomic data from four different countries [16] [17] [18] [19] [20] further confirmed that OSM and OSMR are consistently overexpressed in the intestinal mucosa of patients with active IBD (total control n = 99; total with IBD n = 370; Supplementary  Table 3 ). Neither OSM nor OSMR expression was correlated with standard clinical parameters, including gender, age at diagnosis, disease duration, serum c-reactive protein (CRP), peripheral blood leukocyte count, or treatment with pharmacological therapies; however, OSM and OSMR expression were increased in patients with IBD who required surgery, which suggests an association with treatmentresistant or complicated disease (Supplementary Fig. 1) .
OSM is correlated with response to TNF-neutralizing therapy Hierarchical clustering of cytokine and chemokine expression in two cohorts with IBD revealed that OSM is consistently associated with a discrete module of inflammatory mediators ( Fig. 2a and Supplementary Fig. 2) . Although molecular correlates of anti-TNF response have been reported previously, there are currently no clinically accepted predictive biomarkers of anti-TNF response for IBD 18, [21] [22] [23] . We therefore asked whether the OSM-associated inflammatory module was associated with responsiveness to anti-TNF therapy. Among patients refractory to corticosteroids or other immunosuppressive therapies, unsupervised hierarchical clustering that was based on the expression of OSM-associated module genes revealed that high module expression in pretreatment biopsies was strongly associated with primary nonresponsiveness to anti-TNF therapy ( Fig. 2b and Supplementary Fig. 3a,b) . Complete mucosal healing (determined on the basis of endoscopic and histological criteria) following infliximab (Remicade) therapy was achieved by 69-85% of patients with low OSM module expression, but was observed in only 10-15% of those with high OSM module expression ( Fig. 2c and Supplementary Fig. 3b ). Notably, individual expression of OSM and OSMR at baseline was strongly associated with poor primary response to infliximab in three different cohorts ( Fig. 1d and Supplementary  Fig. 3c,d) 18, 22, 23 . Indeed, at the whole-transcriptome level, OSM was among the 20 most strongly expressed genes in patients with anti-TNF-resistance, as compared to those who responded to anti-TNF (Supplementary Table 4 ). Baseline OSM and OSMR expression levels were also elevated in patients who responded initially to infliximab, but relapsed by week 30 after treatment (Supplementary Fig. 3d) .
The association between mucosal OSM expression and anti-TNF response was confirmed in two additional prospective patient cohorts from phase 3 clinical trials of moderate-to-severely active UC, one treated with intravenous infliximab ( Fig. 2e-g) , and the other treated with subcutaneous golimumab (Simponi), an alternative anti-TNF agent ( Supplementary Fig. 3e-i) 24, 25 . Unlike the cohorts described above, these trials categorized patients into response groups on the basis of improvement in clinical Mayo scores. This enabled us to assess patients who achieved full remission following therapy, those who partially responded (showing an improvement in Mayo score, but with remaining disease activity), and those who were completely nonresponsive to therapy. Whereas OSM was most highly expressed in the nonresponsive group of patients treated with infliximab ( Fig. 2f) , it was substantially elevated in both nonresponders and partial responders who received golimumab ( Supplementary Fig. 3f ). Although OSM expression is broadly correlated with inflammation severity in the overall IBD-afflicted population ( Fig. 1e) , OSM did not correlate substantially with disease severity in these clinical trial cohorts, which were composed exclusively of patients with high disease activity ( Fig. 2g and Supplementary Fig. 3h ). In addition, baseline disease activity and clinical biomarker expression in these trials were not significantly associated with treatment response ( Fig. 2e and Supplementary Fig. 3e,g) , which suggests that OSM measurement before therapy could yield useful prognostic information that cannot be obtained through conventional clinical assessment. Thus, analysis of five data sets (comprising 227 patients) demonstrates that high baseline OSM expression in the intestinal mucosa is reproducibly associated with decreased responsiveness to anti-TNF therapy.
Intestinal stromal cells express abundant OSMR
To gain insight into the role of OSM in the intestine, we conducted gene-ontology network analysis of human IBD transcriptomic data using ClueGo 26 . Relative to TNF-high tissues (used as a control for generic inflammation), OSM-high and OSMR-high tissues were strongly enriched in genes related to leukocyte chemotaxis, extracellular matrix organization, and mesenchymal development, which suggests that OSM might influence nonhematopoietic stromal cells ( Supplementary Fig. 4 ). Indeed, in mucosal biopsies from healthy donors and patients with IBD analyzed using RT-qPCR, OSMR expression was closely correlated with the well-established fibroblast products collagen type 1 alpha 1 chain (COL1A1) and fibroblast activation protein-α (FAP), as well as the lymphoid-tissue-like stromal markers podoplanin (PDPN, also known as gp38) and intercellular adhesion molecule 1 (ICAM1) ( Fig. 3a) [27] [28] [29] [30] [31] [32] . All of these stromal genes were highly expressed in inflamed IBD specimens (Fig. 3b) . Furthermore, stromal cells with high PDPN expression were abundant in the colon lamina propria of patients with CD or UC ( Fig. 3c) .
Flow cytometry analysis of human intestinal mucosa revealed that OSMR is undetectable in epithelial and hematopoietic cells, expressed in low amounts by endothelial cells, and strongly expressed by the majority of CD45 − EpCAM − CD31 − stromal cells ( Fig. 3d-f ). By contrast, OSM was expressed by various hematopoietic populations in human intestinal mucosa, including CD4 + T cells and HLA-DR + antigen-presenting cells from both controls and patients with IBD ( Supplementary Fig. 5a-d) .
Notably, OSMR was expressed more abundantly than the related IL-6 receptor by intestinal stromal cells from both healthy controls and patients with IBD ( Supplementary Fig. 5g ). OSM stimulation elicited phosphorylation of STAT3, STAT1, Akt, and ERK1/2 MAP kinases in cells of the primary human intestinal stromal cell line CCD-18Co, whereas IL-6 triggered only STAT3 phosphorylation ( Fig. 3g) . OSMR expression in different cell populations was equivalent in healthy controls and patients with IBD in terms of both the frequency of OSMR high cells ( Fig. 3h ) and OSMR expression intensity (Fig. 3i) . This suggests that the increased OSMR expression observed in biopsies from patients with IBD ( Fig. 1) is due to an accumulation of OSMRexpressing stromal cells in the tissue, not increased OSMR expression per cell. Because stromal cells vastly outnumber endothelial cells in the intestine (Supplementary Fig. 5h ) and are highly enriched in OSMR, stromal cells seem to be the dominant intestinal OSMR + population. Intriguingly, OSMR high stromal cells coexpressed PDPN and ICAM1, a phenotype that is similar to that of fibroblastic reticular cells (FRCs) in secondary lymphoid tissue ( Fig. 3j) 33 .
OSM promotes inflammatory activity in the intestinal stroma
To assess the response of intestinal stromal cells to OSM, we treated CCD-18Co cells with recombinant human OSM and used RT-qPCR to profile the expression of OSM-associated inflammatory module genes ( Fig. 2a) . Notably, half of the module members, including IL6 and a functionally diverse set of chemokines, were induced directly by OSM stimulation (Fig. 4a) . OSM also induced the expression of ICAM1 and PDPN, which suggests that it might enforce the phenotype of OSMR high stroma observed in vivo (Fig. 3j) . The OSM response was strictly dependent on OSMR, and not on LIFR ( Supplementary Fig. 5i,j) .
To determine whether a similar OSM response can be detected in vivo, we used fluorescence-activated cell sorting (FACS) to purify OSMR high and OSMR low stromal cells from colon tissue of three donors ( Fig. 4b and Supplementary Fig. 5k ). RT-qPCR analysis of the purified cell populations revealed similar expression of classical fibroblast products, including collagens, lumican, fibronectin, and CD90 ( Fig. 4c and Supplementary Fig. 5l ). However, relative to OSMR low cells, OSMR high stroma expressed high amounts of several chemokines and cytokines, including IL6, CCL2, CXCL1, and CXCL10, consistent with the gene induction profile observed in CCD-18Co cells (Fig. 4c) . High OSMR expression might therefore indicate a state of increased inflammatory activity among intestinal stromal cells.
Because OSM is known to synergize with other inflammatory cytokines (in breast cancer, for example), we asked whether OSM and TNF have synergistic effects on human intestinal stroma. Indeed, some genes (such as the CXCR3 ligands CXCL9, CXCL10, and CXCL11) were synergistically induced in CCD-18Co cells by combined OSM and TNF treatment, whereas others, such as CCL2, were not ( Fig. 4d and Supplementary Fig. 5m ). Comparable responses were observed in primary ex vivo cultures of human colonic stromal cells ( Fig. 4e and Supplementary Fig. 5n ). As compared to stromal cells, human umbilical vein endothelial cells (HUVECs) were weakly responsive to OSM, consistent with lower endothelial expression of OSMR ( Supplementary Fig. 5o,p) . Intriguingly, stromal cells from patients with IBD were more sensitive to stimulation with OSM and/ or TNF than stromal cells from non-IBD controls (Fig. 4f) .
The OSM-stromal cell axis is conserved in mice To explore the OSM-stromal axis in a relevant preclinical setting, we used a model IBD system driven by oral Helicobacter hepaticus infection and systemic IL-10 receptor blockade in wild-type C57BL/6 mice (Hh + α-IL-10R model; Fig. 5a ) 34, 35 . This causes T cell-dependent pathology that is resistant to anti-TNF therapy ( Supplementary  Fig. 6a ) 36 . Furthermore, this model does not require signaling by IL-6, IL-1α, or IL-1β ( Supplementary Fig. 6b,c) . At peak disease severity, colonic lamina propria leukocytes increased tenfold in abundance ( Fig. 5b) . Osm and Osmr were highly expressed in the colons of mice with colitis ( Fig. 5c) IL1B  IL8  IL6  CCL3  CCL4  IL11  CSF3  IL1A  CSF2  IL22  IFNG  CCL2  IL17A  CXCL3  CXCL2  CXCL5  CXCL6  CXCL1  CXCL9  CXCL10  CXCL11   Identify consistently  OSM-associated  genes   IL1B  IL1A  IL6  IL11   CSF2  CSF3  IFNG  IL17A  IL22 Cytokines explant supernatants and fecal matter of colitic animals the (Fig. 5d) .
The expression kinetics of OSM in vivo closely mirrored those of IL-6, IL-1β, and TNF, but differed substantially from those of IL-23, which is required at early time-points for the induction of colitogenic T cell responses ( Supplementary Fig. 6d ) 34, 37 . As in humans, mouse Osm displayed a hematopoietic expression pattern with relative enrichment in antigen-presenting cells, according to RT-qPCR analysis of FACS-sorted colon populations from healthy mice and those with colitis ( Fig. 5e and Supplementary Fig. 6e ). By contrast, Osmr expression was restricted to intestinal stromal cells in both healthy and inflamed animals (Fig. 5e) . The colon stroma from mice with inflammation also expressed high amounts of Il1b and Il6, which suggests that these cells adopt a proinflammatory state during colitis ( Fig. 5e) . Furthermore, the colon lamina propria of colitic mice was highly enriched in PDPN + stromal cells, consistent with human IBD (Fig. 5f) . To determine the location of OSMR-expressing cells in the intestine, we used RNAscope in situ hybridization. Osmr expression in healthy mouse colon tissue was detected in endothelial and stromal cells. OSMR-expressing stromal cells were distributed widely within the lamina propria along the entire length of the crypt-villus axis, as well as in lymphoid clusters. No expression was observed in epithelial cells, and a similar expression pattern was observed in the ileum (Supplementary Fig. 7a ). In agreement with our observations of increased numbers of PDPN + stromal cells and increased OSMR expression in inflamed colon tissue, the number of cells expressing Osmr was markedly increased in the lamina propria of mice with colitis ( Fig. 5g) . Mouse colon stromal cells responded strongly to OSM in a manner similar to that of human stroma (Supplementary Fig. 7) . By contrast, substantial OSM responsiveness was not observed in CD45 + leukocytes from mouse spleen or colon or from mouse colonic epithelial organoids (Supplementary Fig. 7) . Taken together, these data indicate that the intestinal OSM biology of mice and humans is largely consistent.
OSM drives colitis in a preclinical model of anti-TNF-resistant IBD
To determine whether OSM can influence anti-TNF-resistant colitis, we compared OSM-deficient mice (Osm −/− ) to co-housed wild-type littermates by using the Hh + α-IL-10R model. At steady state, Osm −/− mice showed normal organ histology (Supplementary Fig. 8a) , normal development of secondary and mucosal-associated lymphoid tissue (Supplementary Fig. 8b-d) , a normal leukocyte repertoire in lymphoid and intestinal tissue, and normal frequencies of nonhematopoietic cells in the colon (Supplementary Fig. 9 ). At peak disease severity, Osm −/− mice displayed reduced colon pathology, according to colonoscopy and histological assessment, when compared to wildtype controls. This was particularly clear when we assessed features of severe disease, including crypt abscess formation, submucosal inflammation, and edema ( Fig. 6a-d) . This was not due to differences in H. hepaticus colonization (Supplementary Fig. 9k) .
Notably, Osm −/− colons displayed normal activation of chemokine and cytokine expression during the first week of colitis, as well as normal accumulation of leukocyte populations in the lamina propria ( Fig. 6e  and Supplementary Fig. 10a-d) . However, this response was attenuated during week 2, in parallel with reduced accumulation of CD4 + T cells and granulocytes. Reduced proliferation of colonic CD4 + T cells (as determined by Ki67 staining) could not explain the differences in T cell abundance, and leukocyte accumulation in Osm −/− mesenteric lymph nodes was entirely normal (Supplementary Fig. 10e,f) . This suggests that OSM has little influence on the early phase of inflammation but enhances inflammation at later time points by promoting stromal chemokine production and selective recruitment of CD4 + T cells and granulocytes. To confirm that the trafficking of OSM + TNF OSM TNF OSM + TNF OSM Osm −/− leukocytes during acute inflammation is normal, we employed a model of skin inflammation that involves topical application of imiquimod (a toll-like receptor 7 agonist) to mouse ears over 6 d. Consistent with early colon inflammation, Osm −/− and wild-type littermates showed equivalent skin thickening and recruitment of monocytes, granulocytes, and T cells to skin and cervical lymph nodes (Supplementary Fig. 10g-l) . Notably, in the Hh + α-IL-10R model of colitis, Osm −/− mice displayed reduced colon expression of the OSM-associated inflammatory module that is associated with anti-TNF resistance in humans (Supplementary Fig. 11a ).
OSM neutralization suppresses anti-TNF-resistant colitis in mice
To test the therapeutic utility of OSM, we treated wild-type C57BL/6 mice with an Fc-tagged soluble OSMR-gp130 fusion protein (OR-Fc; Fig. 6f and Supplementary Fig. 11b ) 38 , starting at day 7 of the Hh + α-IL-10R protocol, by which time colitis is readily detectable Supplementary Fig. 11c) . As compared to commercially available polyclonal anti-OSM antibodies, the OR-Fc construct was more efficient at neutralizing OSM in an ex vivo mouse intestinal stromal cell assay (Supplementary Fig. 11b ). OR-Fc treatment significantly reduced colitis severity as compared to mock treatment (recombinant Fc protein), which demonstrates the potential utility of OSM as a therapeutic target (Fig. 6g,h and Supplementary Fig. 11d ). Consistent with Osm −/− mice, colonic expression of the clinically relevant OSMassociated inflammatory module during colitis was suppressed by therapeutic OSM blockade (Fig. 6i) . Every 48 h:
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DISCUSSION
IBD is a clinically challenging illness that strikes at a young age and causes lifelong morbidity. The high rate of primary and acquired resistance to therapy makes IBD a notable area of unmet medical need, for which alternative therapeutic options and improved patient stratification methods are required. Although cytokines are well known to mediate intestinal inflammation, few have proven to be useful as therapeutic targets 5 . The notable exception is TNF, the neutralization of which has been profoundly successful for the treatment of IBD. More recently, the IL-12-IL-23 neutralizing antibody ustekinumab has also shown clinical efficacy for CD 39 . Nevertheless, treatment resistance remains a substantial clinical challenge, which makes the identification of alternative therapeutic targets an urgent priority.
To identify such targets, we profiled cytokine expression in healthy individuals and patients with IBD. This revealed OSM to be consistently overexpressed in inflamed intestinal tissue from mice and humans. Hematopoietically derived OSM seems to mediate intestinal pathology by promoting inflammatory behavior in gutresident stromal cells, revealing a novel system of leukocyte-stromal cell cross-talk that might have relevance in multiple mucosal tissues. OSM is expressed as part of a core inflammatory cytokine module that includes IL-6 and IL-1α/β, with effects that are distinct from the closely related IL-6 and synergistic with those of TNF. Whereas IL-23 is a crucial trigger of bacterially driven colitis through its actions on T cells 34, 37 , OSM might act as an inflammatory amplifier and driver of disease chronicity by promoting chemokine, cytokine, and adhesion-factor production by intestinal stromal cells ( Supplementary  Fig. 11e ). Whether OSM can influence tissue fibrosis via the stromal compartment remains to be determined. Intriguingly, OSM has been shown to bind extracellular matrix components (including collagen, laminin, and fibronectin) in a manner that protects it from proteolytic degradation and maintains biological activity for prolonged periods of time 40 . This system could amplify the effects of OSM in chronic inflammation by promoting the accumulation of stable OSM protein, particularly in tissues with high amounts of extracellular matrix deposition.
The immunological importance of intestinal stromal cells is not well understood; although they can respond to microbial challenges and influence dendritic cell function under steady-state conditions 27, 29 , a crucial inflammatory role for stromal cells in IBD has not been demonstrated 28 . Nevertheless, data from other inflammatory diseases, such as rheumatoid arthritis, support the hypothesis that stromal cells are active contributors to immune pathology 41 . The high frequency of fibrotic complications in CD is consistent with a pathological role for intestinal stromal cells. However, we found that inflamed tissue from patients with CD and patients with UC contains large numbers of PDPN + stromal cells, despite UC not being strongly associated with fibrosis. Similarly, mice subjected to Hh + α-IL-10R colitis show a substantial expansion of the intestinal stromal cell compartment in the absence of overt intestinal fibrosis. These observations highlight the possibility that intestinal stromal cells might contribute to inflammatory pathology in ways that extend beyond the simple deposition of extracellular matrix components. A major unanswered question regarding intestinal stromal cells is their ontogeny. Although the number of PDPN + stromal cells clearly increases during intestinal inflammation in both mice and humans, it is unknown whether they arise from the expansion of tissue-resident precursors, are recruited from elsewhere (for example, through circulating precursors), or if they differentiate from a distinct tissue-resident cell type. Similarly, it is not known whether OSMR high intestinal stromal cells represent a distinct mesenchymal lineage or simply a state of increased immunological activity. Also noteworthy is the heightened cytokine sensitivity of intestinal stromal cells from patients with IBD. Although the mechanism underlying this difference is not clear, it might be related to a similar phenomenon observed in fibroblast-like synoviocytes from patients with rheumatoid arthritis, which display imprinted hyperresponsiveness to inflammatory stimuli, possibly owing to mutations and/or epigenetic alterations 41 To assess the role of OSM in a preclinical model of IBD, we chose to employ the Hh + α-IL-10R system. Although several murine models of IBD exist, we chose this system for the following reasons: (i) it does not require the use of genetically modified mice, which precludes the possibility of confounding developmental defects; (ii) in keeping with current concepts of human IBD etiology, it requires dual triggers in the form of infection with the commensal pathobiont H. hepaticus and transient immune dysregulation through IL-10R blockade; (iii) it is driven by a full spectrum of innate and adaptive immune processes, as occurs in patients with IBD; and (iv) it is highly resistant to TNF blockade, which makes it ideal for investigating novel drivers of colitis. We have also observed high expression of OSM in additional mouse models of IBD, including chemically induced colitis and adoptive transfer of naive CD4 + T cells to Rag −/− mice, which suggests that OSM might be relevant beyond the Hh + α-IL-10R model.
In addition to alternative therapeutic targets, patients with IBD would benefit substantially from improved systems for predicting disease course and response to therapy. In the case of anti-TNF therapy, no biomarkers are currently used for predictive purposes in standard clinical practice, and conventional clinical parameters are insufficient to predict therapeutic response 21 . This forces caregivers to make treatment decisions with little knowledge of whether a patient is likely to benefit, which places many patients at unnecessary risk of developing anti-TNF-related complications (for example, infections) 42, 43 , and inflating the economic burden of IBD care. However, we have observed that high OSM expression in intestinal mucosa is reproducibly associated with a high risk of resistance to anti-TNF therapy. Our data thus highlight the potential for developing a robust assay-one based on measuring the expression of OSM or similar inflammatory factors-that could help clinicians determine whether to prescribe anti-TNF antibodies or to explore alternative therapeutic options.
Although OSM can influence tissue remodeling in organs such as the heart and liver [44] [45] [46] [47] [48] , Osm −/− mice are viable and healthy, which suggests that therapeutic blockade of OSM might cause minimal side effects. Indeed, OSM has been targeted for rheumatoid arthritis in phase 1 and 2 clinical trials using a humanized anti-OSM monoclonal antibody (GSK315234) 49 . Although little clinical efficacy was observed, the drug was well tolerated; a dose-related decrease in platelet counts was the most notable adverse effect (although all platelet counts remained within the normal reference range). This is consistent with a prior report that OSMR-deficient mice have modestly reduced platelet counts owing to a reduction in bone marrow megakaryocyte progenitors 50 . Because OSM is implicated as a mediator of nociception 51 and IBD comorbidities such as psoriasis [52] [53] [54] [55] and arthritis [56] [57] [58] [59] [60] , the benefits of OSM blockade in patients with IBD may extend beyond the attenuation of gut inflammation. OSM and OSMR are overexpressed in the vast majority of active IBD lesions, particularly in patients with anti-TNF-resistant disease. OSM could therefore be a novel predictive biomarker of and therapeutic target for this clinically challenging population, and clinical studies to evaluate this hypothesis are warranted.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
Some mice were also treated with a TNF-neutralizing antibody (clone TN3-19.12, Bio X Cell, USA) at a total weekly intraperitoneal dose of 1 mg per animal. This dose was found to completely abrogate intestinal pathology in 129SvEv.Rag −/− mice infected with H. hepaticus (data not shown). For experiments involving anti-IL-6R treatment and C57BL/6.Il1r1 −/− mice, anti-IL-10R was injected once per week (starting at day 0) and animals were killed after 4 weeks. Similarly, anti-IL-6R (clone D7715A7) was administered once per week as a 1 mg intraperitoneal dose starting at day 0. The imiquimod model of skin inflammation is described in Supplementary Methods.
Scoring of mouse colitis. Colonoscopy to assess colitis severity was performed and scored according to the methods of Becker et al. 62 . Histological assessment of colitis severity was performed as described 63 . Briefly, formalin-fixed paraffin-embedded cross-sections of proximal, middle, and distal colon were stained with hematoxylin and eosin and graded on a scale of 0 to 3 for four parameters: epithelial hyperplasia and goblet cell depletion, leukocyte infiltration, area affected, and features of severe disease activity. Common severity features include crypt abscess formation, submucosal leukocyte infiltration, and interstitial edema. Scores for each criterion are added to give an overall score of 0 to 12 per colon section. Data from the three colon regions are then averaged to give an overall score. Scoring was conducted in a blinded fashion and confirmed by an independent blinded observer. Interobserver Pearson correlation coefficients ranged from 0.90 to 0.95.
Mouse colon tissue preparation and cell isolation.
Mouse colons were washed with EDTA to remove epithelium and digested with collagenase VIII to liberate cell populations as described 64 . Tissue digests were separated by centrifugation on a 30%/40%/70% percoll gradient. Cells at the 30%/40% interface were collected as the stroma/epithelium-enriched fraction, whereas cells at the 40%/70% interface were collected as the lamina-propria leukocyte-enriched fraction. For ex vivo stromal culture, stromal fractions were plated and cultured as described 35 . Culture of epithelial organoids is described in Supplementary Methods.
Colon explant cultures.
Mouse proximal colon segments (0.25 cm 2 ) were cultured overnight in RPMI media with 10% FCS and 10,000 U/ml penicillin/ streptomycin. OSM was quantified in the supernatant by ELISA (R&D Systems, UK) and normalized to explant weight.
Stimulation of stromal and endothelial cells. CCD-18Co cells (primary human intestinal fibroblasts; ATCC, not currently listed as misidentified on the ICLAC database) and primary ex vivo stromal cultures were grown in humidified incubators with 5% CO 2 at 37 °C in DMEM media (Sigma-Aldrich) with 10% FCS and 2% human serum (Sigma-Aldrich). HUVEC cells (Gibco) were cultured as above in Medium 200 with low serum growth supplement (Gibco), according to the manufacturer's instructions. For cytokine-stimulation experiments, unless otherwise indicated, all treatments were for 2 h, and all cytokines were administered at a concentration of 10 ng/ml. Cells were cultured for no more than eight passages to avoid onset of senescence, phenotypic drift, and contamination (for example, by mycoplasma). All cytokines were purchased from Peprotech. To knock down OSMR expression in CCD-18Co cells, Accel SMARTpool siRNA was used following manufacturer instructions (GE Healthcare Dharmacon, USA), and cells were stimulated to test for OSM sensitivity after 72 h of transfection.
